A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

NCT04504032 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
497
Enrollment
OTHER
Sponsor class

Stopped Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.

Conditions

Interventions

Sponsor

Gates Medical Research Institute